Publication

Article

Applied Clinical Trials

Applied Clinical Trials-04-01-2025
Volume34
Issue 2

Applied Clinical Trials: April 2025 Interactive Digital Edition

View the Applied Clinical Trials April 2025 issue in an interactive format.

Click here to view our interactive April 2025 issue!

Download Issue PDF
Articles in this issue
Applied Clinical Trials: April 2025 Interactive Digital Edition
Applied Clinical Trials: April 2025 Interactive Digital Edition
What’s Next for DEI?
What’s Next for DEI?
The Impact of DEI Ban On Clinical Research Ecosystem
The Impact of DEI Ban On Clinical Research Ecosystem
Tapping the Patient Voice as a Strategic Differentiator
Tapping the Patient Voice as a Strategic Differentiator
Benchmarking Risks Across Therapeutic Areas
Benchmarking Risks Across Therapeutic Areas
Scaling eSource-Enabled Clinical Trials: Hospital Perspectives
Scaling eSource-Enabled Clinical Trials: Hospital Perspectives

Newsletter

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Subscribe Now!
Related Videos
Related Content
© Matthieu - © Matthieu - stock.adobe.com
August 8th 2025

Zusduri Demonstrates Sustained Efficacy in Phase III ENVISION Trial for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

Andy Studna, Senior Editor
ACT Brief Episode 1: Placebos, Politics, and the Ethics of Vaccine Trials
August 8th 2025

ACT Brief Episode 1: Placebos, Politics, and the Ethics of Vaccine Trials

Applied Clinical Trials Editorial Staff
© Kaikoro - © Kaikoro - stock.adobe.com
August 8th 2025

AI-Powered Non-Interventional Research Delivers What DCTs Promised

Troy Astorino
Unifying Industry to Better Understand GCP Guidance
August 8th 2025

Unifying Industry to Better Understand GCP Guidance

Andy Studna, Senior Editor
© Satjawat - © Satjawat - stock.adobe.com
August 8th 2025

Tegoprazan Shows Superior Maintenance of Healing in Phase III TRIUMpH Study of Gastroesophageal Reflux Disease

Andy Studna, Senior Editor
Credit: Lars Neumann | stock.adobe.com
August 8th 2025

FDA Supports Continued Development of Eftilagimod Alfa in PD-L1–Negative Head and Neck Cancer

Andy Studna, Senior Editor
© 2025 MJH Life Sciences

All rights reserved.